Share Price and Basic Stock Data
Last Updated: January 13, 2026, 7:43 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Pharmaids Pharmaceuticals Ltd, operating in the pharmaceuticals sector, reported a stock price of ₹47.8 and a market capitalization of ₹169 Cr. The company has shown fluctuating sales patterns, with a stark decline in revenue, recording ₹0 in sales for each quarter from September 2022 to September 2023. However, a significant uptick occurred in the trailing twelve months (TTM), with sales rising to ₹25 Cr. for the fiscal year ending March 2025, reflecting a revenue increase from ₹19 Cr. in March 2025. Despite these improvements, the company’s operational performance remains inconsistent, as evidenced by the negative operating profit margins (OPM) that stood at -61.79% in September 2025. This volatility in revenue generation and the lack of consistent sales until recent quarters raises questions about the company’s operational strategy and market positioning.
Profitability and Efficiency Metrics
The profitability metrics for Pharmaids Pharmaceuticals indicate significant challenges. The company reported a net profit of -₹16 Cr. in the TTM, which translates to a net profit margin of -69.44% for March 2025. The operating profit figures also reflect a downward trajectory, with operating profits consistently negative since March 2023, culminating in an operating profit of -₹13 Cr. for March 2025. Efficiency ratios, such as the return on equity (ROE) at 16.3% and return on capital employed (ROCE) at 17.4%, seem robust in isolation; however, they are overshadowed by the company’s ongoing losses. The cash conversion cycle (CCC) of -63 days indicates that the company has been able to convert its investments into cash relatively quickly, but this is not translating into positive profitability. The high interest coverage ratio of -6.06x further underscores the financial strain, indicating that the company is finding it increasingly difficult to meet its interest obligations.
Balance Sheet Strength and Financial Ratios
Pharmaids Pharmaceuticals’ balance sheet reveals a concerning financial structure, with total borrowings reported at ₹20 Cr. against reserves of ₹17 Cr. This indicates a leverage ratio that could pose risks, especially in a sector where liquidity is crucial. The company’s current ratio was reported at 0.77, highlighting potential liquidity issues, as it falls below the typical benchmark of 1.0 for financial health. Additionally, the price-to-book value (P/BV) ratio stood at 4.08x, which suggests that the stock may be overvalued relative to its book value. The asset turnover ratio of 0.18% reflects inefficiencies in asset utilization, further exacerbating the financial strain. Despite these challenges, the company has shown a degree of resilience by maintaining a market capitalization of ₹169 Cr., which indicates some level of investor confidence in its potential recovery.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Pharmaids Pharmaceuticals illustrates a significant shift over time. Promoter holdings have decreased from 16.54% in December 2022 to 32.99% by September 2025, indicating a potential dilution of control or confidence among insiders. Conversely, public shareholding has seen an increase from 83.47% to 67.00%, suggesting that retail investors are becoming more prominent stakeholders. The number of shareholders also reflects a slight increase, standing at 8,027 as of September 2025. This shift may indicate growing interest from the public despite the company’s financial challenges. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could signal a lack of confidence from larger financial entities, which often prefer to invest in companies with stronger fundamentals and more stable financial outlooks.
Outlook, Risks, and Final Insight
Looking ahead, Pharmaids Pharmaceuticals faces a mixed outlook. On one hand, the recent uptick in sales and the stabilization of promoter holdings could signal a potential turnaround. However, substantial risks remain, including ongoing operational losses, high leverage, and liquidity issues. The company must focus on improving its sales performance and operational efficiency to regain investor confidence and stabilize its financial health. Additionally, the lack of institutional backing could hinder its ability to attract significant investment necessary for growth. If the company can successfully navigate these challenges and leverage its recent sales growth, it may position itself for recovery. Conversely, failure to achieve consistent profitability and manage its debt could lead to further financial distress, limiting its operational capabilities in a competitive sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 132 Cr. | 104 | 208/84.3 | 29.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,008 Cr. | 367 | 479/192 | 83.0 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,210.85 Cr | 1,122.54 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 5.81 | 4.73 | 5.24 | 4.71 | 4.77 | 6.66 | 8.61 |
| Expenses | 0.54 | 0.69 | 8.60 | 1.61 | 1.02 | 2.45 | 11.39 | 8.14 | 7.65 | 7.60 | 8.67 | 12.03 | 13.93 |
| Operating Profit | -0.54 | -0.69 | -8.60 | -1.61 | -1.02 | -2.43 | -5.58 | -3.41 | -2.41 | -2.89 | -3.90 | -5.37 | -5.32 |
| OPM % | -12,150.00% | -96.04% | -72.09% | -45.99% | -61.36% | -81.76% | -80.63% | -61.79% | |||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.41 | -0.26 | 0.76 | 0.12 | -0.07 | 0.08 | 0.00 | 0.13 | 0.04 | 3.21 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.77 | 0.26 | 0.33 | 0.48 | 1.01 | 1.20 | 1.08 |
| Depreciation | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.04 | 0.63 | 0.57 | 0.61 | 0.64 | 0.62 | 0.61 | 0.47 |
| Profit before tax | -0.55 | -0.70 | -8.60 | -1.21 | -1.29 | -1.73 | -6.86 | -4.31 | -3.27 | -4.01 | -5.40 | -7.14 | -3.66 |
| Tax % | 0.00% | 0.00% | -28.37% | 7.44% | -60.47% | -33.53% | -7.73% | -27.38% | -30.58% | -24.94% | -11.11% | -26.05% | -30.87% |
| Net Profit | -0.55 | -0.71 | -6.16 | -1.30 | -0.50 | -1.15 | -6.33 | -3.12 | -2.27 | -3.01 | -4.80 | -5.27 | -2.53 |
| EPS in Rs | -0.53 | -0.54 | -2.87 | -0.61 | -0.23 | -0.54 | -1.57 | -0.76 | -0.55 | -0.55 | -1.12 | -1.39 | -0.70 |
Last Updated: December 29, 2025, 1:34 pm
Below is a detailed analysis of the quarterly data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8.61 Cr.. The value appears strong and on an upward trend. It has increased from 6.66 Cr. (Jun 2025) to 8.61 Cr., marking an increase of 1.95 Cr..
- For Expenses, as of Sep 2025, the value is 13.93 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.03 Cr. (Jun 2025) to 13.93 Cr., marking an increase of 1.90 Cr..
- For Operating Profit, as of Sep 2025, the value is -5.32 Cr.. The value appears strong and on an upward trend. It has increased from -5.37 Cr. (Jun 2025) to -5.32 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Sep 2025, the value is -61.79%. The value appears strong and on an upward trend. It has increased from -80.63% (Jun 2025) to -61.79%, marking an increase of 18.84%.
- For Other Income, as of Sep 2025, the value is 3.21 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Jun 2025) to 3.21 Cr., marking an increase of 3.17 Cr..
- For Interest, as of Sep 2025, the value is 1.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.20 Cr. (Jun 2025) to 1.08 Cr., marking a decrease of 0.12 Cr..
- For Depreciation, as of Sep 2025, the value is 0.47 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.61 Cr. (Jun 2025) to 0.47 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Sep 2025, the value is -3.66 Cr.. The value appears strong and on an upward trend. It has increased from -7.14 Cr. (Jun 2025) to -3.66 Cr., marking an increase of 3.48 Cr..
- For Tax %, as of Sep 2025, the value is -30.87%. The value appears to be improving (decreasing) as expected. It has decreased from -26.05% (Jun 2025) to -30.87%, marking a decrease of 4.82%.
- For Net Profit, as of Sep 2025, the value is -2.53 Cr.. The value appears strong and on an upward trend. It has increased from -5.27 Cr. (Jun 2025) to -2.53 Cr., marking an increase of 2.74 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.70. The value appears strong and on an upward trend. It has increased from -1.39 (Jun 2025) to -0.70, marking an increase of 0.69.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:48 am
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Sales | 4 | 0 | 15 | 19 | 25 |
| Expenses | 4 | 10 | 27 | 32 | 42 |
| Operating Profit | 0 | -10 | -12 | -13 | -17 |
| OPM % | 3% | -82% | -66% | -71% | |
| Other Income | 0 | 0 | 0 | 0 | 3 |
| Interest | 0 | 0 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 2 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -17 | -20 |
| Tax % | 0% | -24% | -24% | -22% | |
| Net Profit | 0 | -8 | -12 | -14 | -16 |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.06 | -3.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | -16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% |
Pharmaids Pharmaceuticals Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| TTM: | 102% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 70% |
| 3 Years: | 67% |
| 1 Year: | 53% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -20% |
| Last Year: | -16% |
Last Updated: September 5, 2025, 12:30 pm
Balance Sheet
Last Updated: December 4, 2025, 1:49 am
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 24 | 17 |
| Borrowings | 0 | 0 | 9 | 39 | 20 |
| Other Liabilities | 2 | 2 | 11 | 22 | 26 |
| Total Liabilities | 11 | 25 | 91 | 120 | 98 |
| Fixed Assets | 0 | 0 | 63 | 77 | 55 |
| CWIP | 0 | 2 | 7 | 5 | 3 |
| Investments | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 11 | 19 | 21 | 39 | 41 |
| Total Assets | 11 | 25 | 91 | 120 | 98 |
Below is a detailed analysis of the balance sheet data for Pharmaids Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00 Cr..
- For Reserves, as of Sep 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 7.00 Cr..
- For Borrowings, as of Sep 2025, the value is 20.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 39.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 19.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 4.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 98.00 Cr.. The value appears to be improving (decreasing). It has decreased from 120.00 Cr. (Mar 2025) to 98.00 Cr., marking a decrease of 22.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 77.00 Cr. (Mar 2025) to 55.00 Cr., marking a decrease of 22.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 98.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 98.00 Cr., marking a decrease of 22.00 Cr..
However, the Borrowings (20.00 Cr.) are higher than the Reserves (17.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Free Cash Flow | 0.00 | -10.00 | -21.00 | -52.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Debtor Days | 124 | 65 | 59 | |
| Inventory Days | 91 | 0 | 112 | 359 |
| Days Payable | 236 | 159 | 480 | |
| Cash Conversion Cycle | -21 | 17 | -63 | |
| Working Capital Days | -18 | -69 | -160 | |
| ROCE % | -64% | -26% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Diluted EPS (Rs.) | -3.05 | -3.56 | -5.86 | 0.14 |
| Cash EPS (Rs.) | -3.14 | -2.87 | -3.52 | 0.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.82 | 19.99 | 10.47 | 8.44 |
| Revenue From Operations / Share (Rs.) | 5.51 | 4.28 | 0.00 | 3.84 |
| PBDIT / Share (Rs.) | -3.59 | -3.50 | -4.61 | 0.14 |
| PBIT / Share (Rs.) | -4.28 | -3.98 | -4.62 | 0.13 |
| PBT / Share (Rs.) | -4.90 | -4.43 | -4.62 | 0.13 |
| Net Profit / Share (Rs.) | -3.83 | -3.36 | -3.52 | 0.14 |
| NP After MI And SOA / Share (Rs.) | -3.06 | -2.26 | -3.52 | 0.14 |
| PBDIT Margin (%) | -65.06 | -81.57 | 0.00 | 3.86 |
| PBIT Margin (%) | -77.61 | -92.99 | 0.00 | 3.63 |
| PBT Margin (%) | -88.85 | -103.37 | 0.00 | 3.56 |
| Net Profit Margin (%) | -69.44 | -78.36 | 0.00 | 3.68 |
| NP After MI And SOA Margin (%) | -55.41 | -52.72 | 0.00 | 3.68 |
| Return on Networth / Equity (%) | -18.16 | -11.05 | -33.64 | 1.67 |
| Return on Capital Employeed (%) | -16.56 | -17.61 | -44.09 | 1.64 |
| Return On Assets (%) | -8.99 | -8.72 | -30.72 | 1.30 |
| Long Term Debt / Equity (X) | 0.50 | 0.04 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.59 | 0.07 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.18 | 0.26 | 0.00 | 0.00 |
| Current Ratio (X) | 0.77 | 1.17 | 8.23 | 1.09 |
| Quick Ratio (X) | 0.35 | 0.85 | 8.23 | 0.72 |
| Inventory Turnover Ratio (X) | 2.47 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -6.06 | -7.86 | -2135.71 | 55.63 |
| Interest Coverage Ratio (Post Tax) (X) | -5.42 | -6.55 | -1631.24 | 54.05 |
| Enterprise Value (Cr.) | 271.01 | 182.39 | 34.01 | 12.44 |
| EV / Net Operating Revenue (X) | 13.94 | 12.07 | 0.00 | 3.16 |
| EV / EBITDA (X) | -21.42 | -14.79 | -3.44 | 81.73 |
| MarketCap / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| Price / BV (X) | 4.08 | 2.55 | 2.08 | 1.48 |
| Price / Net Operating Revenue (X) | 12.45 | 12.14 | 0.00 | 3.26 |
| EarningsYield | -0.04 | -0.04 | -0.16 | 0.01 |
After reviewing the key financial ratios for Pharmaids Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has increased from -3.56 (Mar 24) to -3.05, marking an increase of 0.51.
- For Cash EPS (Rs.), as of Mar 25, the value is -3.14. This value is below the healthy minimum of 3. It has decreased from -2.87 (Mar 24) to -3.14, marking a decrease of 0.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.82. It has decreased from 19.99 (Mar 24) to 16.82, marking a decrease of 3.17.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.51. It has increased from 4.28 (Mar 24) to 5.51, marking an increase of 1.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -3.59. This value is below the healthy minimum of 2. It has decreased from -3.50 (Mar 24) to -3.59, marking a decrease of 0.09.
- For PBIT / Share (Rs.), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 0. It has decreased from -3.98 (Mar 24) to -4.28, marking a decrease of 0.30.
- For PBT / Share (Rs.), as of Mar 25, the value is -4.90. This value is below the healthy minimum of 0. It has decreased from -4.43 (Mar 24) to -4.90, marking a decrease of 0.47.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.83. This value is below the healthy minimum of 2. It has decreased from -3.36 (Mar 24) to -3.83, marking a decrease of 0.47.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.06. This value is below the healthy minimum of 2. It has decreased from -2.26 (Mar 24) to -3.06, marking a decrease of 0.80.
- For PBDIT Margin (%), as of Mar 25, the value is -65.06. This value is below the healthy minimum of 10. It has increased from -81.57 (Mar 24) to -65.06, marking an increase of 16.51.
- For PBIT Margin (%), as of Mar 25, the value is -77.61. This value is below the healthy minimum of 10. It has increased from -92.99 (Mar 24) to -77.61, marking an increase of 15.38.
- For PBT Margin (%), as of Mar 25, the value is -88.85. This value is below the healthy minimum of 10. It has increased from -103.37 (Mar 24) to -88.85, marking an increase of 14.52.
- For Net Profit Margin (%), as of Mar 25, the value is -69.44. This value is below the healthy minimum of 5. It has increased from -78.36 (Mar 24) to -69.44, marking an increase of 8.92.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -55.41. This value is below the healthy minimum of 8. It has decreased from -52.72 (Mar 24) to -55.41, marking a decrease of 2.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is -18.16. This value is below the healthy minimum of 15. It has decreased from -11.05 (Mar 24) to -18.16, marking a decrease of 7.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is -16.56. This value is below the healthy minimum of 10. It has increased from -17.61 (Mar 24) to -16.56, marking an increase of 1.05.
- For Return On Assets (%), as of Mar 25, the value is -8.99. This value is below the healthy minimum of 5. It has decreased from -8.72 (Mar 24) to -8.99, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.50, marking an increase of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.07 (Mar 24) to 0.59, marking an increase of 0.52.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has decreased from 0.26 (Mar 24) to 0.18, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has decreased from 1.17 (Mar 24) to 0.77, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has decreased from 0.85 (Mar 24) to 0.35, marking a decrease of 0.50.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.47. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.47, marking an increase of 2.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -6.06. This value is below the healthy minimum of 3. It has increased from -7.86 (Mar 24) to -6.06, marking an increase of 1.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -5.42. This value is below the healthy minimum of 3. It has increased from -6.55 (Mar 24) to -5.42, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 271.01. It has increased from 182.39 (Mar 24) to 271.01, marking an increase of 88.62.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.94. This value exceeds the healthy maximum of 3. It has increased from 12.07 (Mar 24) to 13.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is -21.42. This value is below the healthy minimum of 5. It has decreased from -14.79 (Mar 24) to -21.42, marking a decrease of 6.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 2.55 (Mar 24) to 4.08, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 12.45. This value exceeds the healthy maximum of 3. It has increased from 12.14 (Mar 24) to 12.45, marking an increase of 0.31.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pharmaids Pharmaceuticals Ltd:
- Net Profit Margin: -69.44%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.56% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -18.16% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -5.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.35
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -69.44%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Unit 201, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Shankarappa Nagaraja Vinaya Babu | Chairman, Non Ind & Non Exe Director |
| Ms. Mini Manikantan | Executive Director |
| Mr. Venu Madhava Kaparthy | Executive Director |
| Mr. Shreedhara Shetty | Non Exe.Non Ind.Director |
| Mr. Methuku Nagesh | Independent Director |
| Mr. P N Vijay | Independent Director |
| Mr. Mopperthy Sudheer | Independent Director |
FAQ
What is the intrinsic value of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd's intrinsic value (as of 13 January 2026) is ₹29.33 which is 38.25% lower the current market price of ₹47.50, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹168 Cr. market cap, FY2025-2026 high/low of ₹78.4/42.0, reserves of ₹17 Cr, and liabilities of ₹98 Cr.
What is the Market Cap of Pharmaids Pharmaceuticals Ltd?
The Market Cap of Pharmaids Pharmaceuticals Ltd is 168 Cr..
What is the current Stock Price of Pharmaids Pharmaceuticals Ltd as on 13 January 2026?
The current stock price of Pharmaids Pharmaceuticals Ltd as on 13 January 2026 is ₹47.5.
What is the High / Low of Pharmaids Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Pharmaids Pharmaceuticals Ltd stocks is ₹78.4/42.0.
What is the Stock P/E of Pharmaids Pharmaceuticals Ltd?
The Stock P/E of Pharmaids Pharmaceuticals Ltd is .
What is the Book Value of Pharmaids Pharmaceuticals Ltd?
The Book Value of Pharmaids Pharmaceuticals Ltd is 14.7.
What is the Dividend Yield of Pharmaids Pharmaceuticals Ltd?
The Dividend Yield of Pharmaids Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Pharmaids Pharmaceuticals Ltd?
The ROCE of Pharmaids Pharmaceuticals Ltd is 17.4 %.
What is the ROE of Pharmaids Pharmaceuticals Ltd?
The ROE of Pharmaids Pharmaceuticals Ltd is 16.3 %.
What is the Face Value of Pharmaids Pharmaceuticals Ltd?
The Face Value of Pharmaids Pharmaceuticals Ltd is 10.0.